Resources Repository
-
ArticlePublication 2018Consequences of a Cigarette Price Increase in 13 Middle Income Countries
This study used extended cost-effectiveness analysis to examine the impact of a 50% increase in …
This study used extended cost-effectiveness analysis to examine the impact of a 50% increase in market prices of cigarettes on health, poverty, and financial protection for men in 13 middle income countries. A 50% increase in cigarette prices would lead to about 450 million years of life gained across the 13 countries from smoking cessation, with half of these in China. Across all countries, men in the bottom income group would gain 6.7 times more…
Mathematical Models | Health/Medicine | Global | Social Determinants | Priority Setting/Ethics | Cost-Effectiveness Analysis | Chronic Disease/Risk | Policy/Regulation -
DataPublication 2019Global Multidimensional Poverty Index 2019: Illuminating Inequalities
This data publication developed by the United Nations Development Programme (UNDP) and the Oxford Poverty …
This data publication developed by the United Nations Development Programme (UNDP) and the Oxford Poverty and Human Development Initiative (OPHI) offers data for 101 countries and 5.7 billion people, comparing acute multidimensional poverty at regional, national, and subnational levels using the global Multidimensional Poverty Index (MPI). The global MPI, developed by the OPHI in 2010, is one tool to comprehensively measure progress towards Sustainable Development Goal (SDG) 1, which aims to end poverty in all…
Health Outcomes | Education/Labor | Global | Social Determinants | Health Systems | Climate/Environment | Economics/Finance -
Teaching PackPublication, Teaching Resource 2022Teaching Pack: Extended Cost-Effectiveness Analysis
This teaching pack, curated by the Center for Health Decision Science, features videos introducing extended …
This teaching pack, curated by the Center for Health Decision Science, features videos introducing extended cost-effectiveness analysis (ECEA) and detailing how it is conducted, and assembles ECEA publications and teaching materials. In addition to the videos, this teaching pack includes a glossary and tutorial. Videos include: Video 1. Introduction to ECEA (~2 min) Video 2. Quantifying Health Benefits (~4 min) Video 3. Private Expenditures Averted (~3 min) Video 4. Financial Risk Protection (~5 min) Video 5.…
Health Outcomes | Health/Medicine | Global | Social Determinants | Priority Setting/Ethics | Costing Methods | Cost-Effectiveness Analysis | Health Systems | Policy/Regulation | Economics/Finance -
ReportPublication 2019Top 10 Health Economics and Outcomes Research Trends
As governments and other payers struggle with provision of the best possible health outcomes at …
As governments and other payers struggle with provision of the best possible health outcomes at affordable costs, the field of health economics and outcomes research (HEOR) has experienced rapid growth. The International Society for Pharmacoeconomics Outcomes Research (ISPOR) produced the ISPOR 2019 Top 10 HEOR Trends which serves to outline the top 10 that the Society members identified that will be the most impactful during 2019. Development of this report included a comprehensive review and…
Health Outcomes | Health/Medicine | Global | Social Determinants | Health Systems | Policy/Regulation | Global Governance | Science/Technology -
ReviewPublication 2018Equity Considerations in CEA: Rotavirus Vaccine in LMIC's
The authors used a systematic review of the literature to identify economic evaluations of rotavirus …
The authors used a systematic review of the literature to identify economic evaluations of rotavirus vaccine in LMICs and assess the extent to which equity was considered in the objectives, analysis, and results. They used equity-related indicators provided in the Guidance on Priority Setting in Health Care (GPS-Health) checklist criteria resulting in 18 unique indicators tracked. The authors found that some articles incorporated the indicators in their model inputs (20%) while the majority (80%) presented…
Evidence Synthesis | Health/Medicine | Global | Social Determinants | Cost-Effectiveness Analysis | Infectious Diseases -
Working PaperPublication 2018Valuing Mortality Risk Reductions in Global Benefit-Cost Analysis
Increasing life expectancy is a major goal of many policies implemented around the world. As …
Increasing life expectancy is a major goal of many policies implemented around the world. As a result, the value of reducing mortality risk has been extensively studied and several organizations have developed recommendations for estimating these values in benefit-cost analysis. However, both the recommendations and the underlying research primarily address high-income settings, raising questions about the extent to which the results are applicable in low- and middle-income countries. The recommendations are also diverse, reflecting differing…
Health Outcomes | Health/Medicine | Global | Social Determinants | Preferences/Values | Priority Setting/Ethics | Decision Analysis | Benefit-Cost Analysis | Policy/Regulation | Economics/Finance -
Working PaperPublication 2018Valuing Nonfatal Health Risk Reductions
This paper explores approaches for valuing nonfatal risk reductions associated with policy choices in low- …
This paper explores approaches for valuing nonfatal risk reductions associated with policy choices in low- and middle-income countries. The approach for valuation ideally would be based on estimates of individuals’ willingness to pay for changes in their own risks. However, high quality valuation research is not available for many nonfatal conditions even in high-income settings. Typically, two approaches are used either alone or in combination as rough proxies. The first involves applying an estimate of…
Health Outcomes | Health/Medicine | Global | Social Determinants | Preferences/Values | Priority Setting/Ethics | Decision Analysis | Benefit-Cost Analysis | Policy/Regulation | Economics/Finance | Critical Thinking/Analysis -
ReviewPublication 2012Modeling Preventative Strategies Against HPV-Related Disease in Developed Countries
This review article is part of a special supplement on “Comprehensive Control of HPV Infections …
This review article is part of a special supplement on “Comprehensive Control of HPV Infections and Related Diseases.” At the time of its writing, prophylactic vaccination against human papillomavirus (HPV) in pre-adolescent females had been introduced in most developed countries, supported by modeled evaluations that had almost universally found vaccination of pre-adolescent females to be cost-effective. Vaccination of pre-adolescent males had been shown to be cost-effective at a cost per vaccinated individual of ~US$400-500 if…
Mathematical Models | Health/Medicine | Global | Social Determinants | Cost-Effectiveness Analysis | Chronic Disease/Risk | Health Systems